Last reviewed · How we verify
NCT06246786
Breast/Cyclosporin A/TNBC (Triple Negative Breast Cancer)
EARLY_PHASE1 trial testing Cyclosporin A in Triple Negative Breast Cancer. Withdrawn.
23 June 2025
Quick facts
| Lead sponsor | Virginia G. Kaklamani |
|---|---|
| Phase | EARLY_PHASE1 |
| Status | Withdrawn |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Start date | 1 July 2024 |
| Primary completion | 23 June 2025 |
| Estimated completion | 23 June 2025 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Cyclosporin A — full drug profile →
Conditions studied
- Triple Negative Breast Cancer — all drugs for Triple Negative Breast Cancer →
- DNA Damage Repair Deficiency — all drugs for DNA Damage Repair Deficiency →
Sponsor
Virginia G. Kaklamani
Who can join
18 and older, any sex, with Triple Negative Breast Cancer or DNA Damage Repair Deficiency. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This will be a single arm, non-randomized, pre-surgical clinical trial of women with newly diagnosed triple negative breast cancer with high g-H2Ax (gamma H2AX antibodies) comparing changes in biomarkers from a diagnostic core needle biopsy to surgical pathology specimen or repeat core needle biopsy.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06246786
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Cyclosporin A
Trials testing the same drug.
- NCT06525948 — Efficacy and Safety of rhTPO in Combination With Cyclosporine Versus Cyclosporine Alone in the Treatment of TD-NSAA · Phase 4 · not yet recruiting
- NCT04945096 — Outcomes of Patients After Allo-HSCT With Decitabine and NAC · Phase 3 · unknown
- NCT04376528 — Mycophenolate Mofetil Versus Cyclosporin A in the Treatment of Primary Biliary Cholangitis-autoimmune Hepatitis Overlap · Phase 4 · unknown
- NCT04537689 — Outcomes With Treatment and Withdraw of Ixekizumab in Patients With Plaque Psoriasis · Phase 4 · recruiting
- NCT04688021 — A Single-arm Trial of Prophylactic Tocilizumab for Acute GVHD Prevention After Haploidentical HSCT. · Phase 2 · unknown
Other recruiting trials for Triple Negative Breast Cancer
Currently open trials in the same condition.
- NCT07533123 — A Phase III Study of JSKN016 Versus Treatment of Physician's Choice in Patients With Triple-Negative Breast Cancer Who H · Phase 3 · recruiting
- NCT07503808 — A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types · Phase 1 · recruiting
- NCT07340541 — Evolutionary Clinical Trial for Novel Biomarker-Driven Therapies · Phase 2 · recruiting
- NCT07281976 — A Trial of LBL-024 Monotherapy or Combination Drug in Patients With Triple Negative Breast Cancer · Phase 1, PHASE2 · recruiting
- NCT06225505 — Early Detection of Triple Negative Breast Cancer Relapse (CUPCAKE) · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06246786 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Virginia G. Kaklamani
- Last refreshed: 16 July 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06246786.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing